losartan has been researched along with Acute Coronary Syndrome in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Angiotensin II type 1 receptor blocker losartan is potentially useful in controlling the central blood pressure and arterial stiffness in mild to moderate essential hypertension, while the effects of losartan in aged patients with essential hypertension are not entirely investigated." | 7.91 | Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension. ( Fei, JC; Guo, T; Li, MM; Lv, YH; Miao, Z; Ou, WS; Wang, BX; Wang, SX; Zhang, ZM, 2019) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 7.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| " Angiotensin II type 1 receptor blocker losartan is potentially useful in controlling the central blood pressure and arterial stiffness in mild to moderate essential hypertension, while the effects of losartan in aged patients with essential hypertension are not entirely investigated." | 3.91 | Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension. ( Fei, JC; Guo, T; Li, MM; Lv, YH; Miao, Z; Ou, WS; Wang, BX; Wang, SX; Zhang, ZM, 2019) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 3.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "Hypertrophic cardiomyopathy is a well-known clinical entity." | 2.49 | Apical hypertrophic cardiomyopathy--case report and review of the literature. ( Caglar, I; Karakaya, O; Ugurlucan, M; Ungan, I; Vural, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Almengló, C | 1 |
| Couselo-Seijas, M | 1 |
| Agra, RM | 1 |
| Varela-Román, A | 1 |
| García-Acuña, JM | 1 |
| González-Peteiro, M | 1 |
| González-Juanatey, JR | 1 |
| Eiras, S | 1 |
| Álvarez, E | 1 |
| Zhang, ZM | 1 |
| Wang, BX | 1 |
| Ou, WS | 1 |
| Lv, YH | 1 |
| Li, MM | 1 |
| Miao, Z | 1 |
| Wang, SX | 1 |
| Fei, JC | 1 |
| Guo, T | 1 |
| Caglar, I | 1 |
| Vural, A | 1 |
| Ungan, I | 1 |
| Ugurlucan, M | 1 |
| Karakaya, O | 1 |
| Henriksson, M | 1 |
| Russell, D | 1 |
| Bodegard, J | 1 |
| Kjeldsen, S | 1 |
| Hasvold, P | 1 |
| Stålhammar, J | 1 |
| Levin, LÅ | 1 |
| Kim, KS | 1 |
| Abraham, D | 1 |
| Williams, B | 1 |
| Violin, JD | 1 |
| Mao, L | 1 |
| Rockman, HA | 1 |
| Simões, MV | 1 |
| Marin-Neto, JA | 1 |
| Romano, MM | 1 |
| O'Connell, JL | 1 |
| de Santi, GL | 1 |
| Maciel, BC | 1 |
1 review available for losartan and Acute Coronary Syndrome
| Article | Year |
|---|---|
Apical hypertrophic cardiomyopathy--case report and review of the literature.
Topics: Acute Coronary Syndrome; Aspirin; Cardiomyopathy, Hypertrophic; Echocardiography; Electrocardiograph | 2013 |
5 other studies available for losartan and Acute Coronary Syndrome
| Article | Year |
|---|---|
Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Topics: Acute Coronary Syndrome; ADAM17 Protein; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angio | 2021 |
Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Antihypertensive Agents; China; Cross-Sectional St | 2019 |
Health-care costs of losartan and candesartan in the primary treatment of hypertension.
Topics: Acute Coronary Syndrome; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury.
Topics: Acute Coronary Syndrome; Acute Disease; Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 | 2012 |
Transient left ventricular dysfunction due to stress-induced cardiomyopathy.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; | 2007 |